Nurexone Biologic Inc
F:J90
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Odontoprev SA
BOVESPA:ODPV3
|
BR |
Nurexone Biologic Inc
Operating Expenses
Nurexone Biologic Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Operating Expenses
-$5m
|
CAGR 3-Years
-238%
|
CAGR 5-Years
-123%
|
CAGR 10-Years
-53%
|
|
|
Enerflex Ltd
TSX:EFX
|
Operating Expenses
-CA$272m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-3%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Operating Expenses
-CA$220.7m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-26%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Operating Expenses
-CA$321.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-8%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Operating Expenses
-CA$134m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
5%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Operating Expenses
-$6m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-113%
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's Operating Expenses?
Operating Expenses
-5m
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Operating Expenses amounts to -5m USD.
What is Nurexone Biologic Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-53%
Over the last year, the Operating Expenses growth was -37%. The average annual Operating Expenses growth rates for Nurexone Biologic Inc have been -238% over the past three years , -123% over the past five years , and -53% over the past ten years .
